SCHEMBL4726883

SCHEMBL4726883

O/N=C(/Nc1ccc(F)c(Cl)c1)c1ccco1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.59
MEN1 O00255 8/20 0.59
ALDH1A1 P00352 6/20 0.56
TSHR P16473 2/20 0.56
SMN1; SMN2 Q16637 6/20 0.55
MAPT P10636 5/20 0.55
ALOX15 P16050 2/20 0.55
TP53 P04637 2/20 0.55
MAPK1 P28482 2/20 0.55
GLA P06280 1/20 0.55
GAA P10253 1/20 0.55
HSD17B10 Q99714 1/20 0.55
RAB9A P51151 8/20 0.51
NPC1 O15118 6/20 0.51
CASP3 P42574 1/20 0.51
SENP8 Q96LD8 1/20 0.51
SENP7 Q9BQF6 1/20 0.51
SENP6 Q9GZR1 1/20 0.51
HTT P42858 3/20 0.49
NPSR1 Q6W5P4 2/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4726885 1.00 KMT2A (0.59) KMT2AMEN1ALDH1A1TSHRSMN1; SMN2
SCHEMBL14260118 0.82 KMT2A (0.60) KMT2AMEN1ALDH1A1TSHRSMN1; SMN2
SCHEMBL4725734 0.80 ALDH1A1 (0.48) KMT2AMEN1ALDH1A1TSHRSMN1; SMN2
SCHEMBL4725732 0.80 ALDH1A1 (0.48) KMT2AMEN1ALDH1A1TSHRSMN1; SMN2
SCHEMBL2191190 0.78 KMT2A (0.76) KMT2AMEN1ALDH1A1TSHRSMN1; SMN2
SCHEMBL2191186 0.78 KMT2A (0.76) KMT2AMEN1ALDH1A1TSHRSMN1; SMN2
SCHEMBL4728350 0.78 MEN1 (0.49) KMT2AMEN1ALDH1A1TSHRSMN1; SMN2
SCHEMBL4728352 0.78 MEN1 (0.49) KMT2AMEN1ALDH1A1TSHRSMN1; SMN2
SCHEMBL4728377 0.77 MEN1 (0.51) KMT2AMEN1ALDH1A1TSHRSMN1; SMN2
SCHEMBL4728379 0.77 MEN1 (0.51) KMT2AMEN1ALDH1A1TSHRSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080146624-A1 AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-06-19 US claimed
WO-2008036652-A2 AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-03-27 WO claimed
US-20080146624-A1 AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-06-19 US disclosed
US-20080146624-A1 AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE INCYTE CORPORATION (US) 2008-06-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080146624-A1 AMIDINES AS MODULATORS OF INDOLEAMINE 2,3-DIOXYGENASE IDO1, IDO2, INMT KMT2A 636/4885MEN1 1795/4885ALDH1A1 2238/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.